

## ARIC Manuscript Proposal #2186

**PC Reviewed: 8/13/13**  
**SC Reviewed: \_\_\_\_\_**

**Status: A**  
**Status: \_\_\_\_\_**

**Priority: 2**  
**Priority: \_\_\_\_\_**

### GO ESP Manuscript Proposal Form

INSTRUCTIONS: Please send proposal by e-mail to the ESP P&P Chairs [James Wilson](#), [Charles Kooperberg](#) and the ESP P&P Coordinator [Jenny Schoenberg](#)

Date of Submission: \_\_\_\_\_

Date of ESP GO P&P Approval: \_\_\_\_\_

#### I. ADMINISTRATIVE INFORMATION

1. On behalf of which approved ESP Project Team/Working Group is this proposal being submitted?  
 Lipids Project team

2. Full Title of Proposed Manuscript:  
 Working Title: Identification of novel triglyceride genes in a genetically heterogeneous family  
 Requested Name of Resulting Writing Team (1-3 words): novel triglyceride genes

3. Investigator Information:

<p>a. Convener: Elisabeth Rosenthal          Affiliation: UW          E-Mail Address: <a href="mailto:erosen@uw.edu">erosen@uw.edu</a>          Junior Author Y/N: Yes</p>	<p>b. Co-convener: Gail Jarvik          Affiliation: UW          E-Mail Address: <a href="mailto:gjarvik@medicine.washington.edu">gjarvik@medicine.washington.edu</a>          Junior Author Y/N: No</p>
--	--

4. Names of Proposed ESP GO Writing Team members including affiliations and E-mail addresses.  
 a. I **Elisabeth Rosenthal** attest that all Writing Team members listed below have reviewed and approved this manuscript proposal.

Name/Degree	Affiliation	E-Mail Address	Junior Investigator	Author/Role Contribution	Author Position
Gail Jarvik	UW	<a href="mailto:gjarvik@medicine.washington.edu">gjarvik@medicine.washington.edu</a>	no	Lab head	last
Elisabeth Rosenthal	Primary author	<a href="mailto:erosen@uw.edu">erosen@uw.edu</a>	yes	Primary analyst	first
David R. Crosslin	UW, Jarvik lab	<a href="mailto:davidcr@uw.edu">davidcr@uw.edu</a>	yes	Statistical analyst	middle
Deborah A. Nickerson	UW	<a href="mailto:debnick@uw.edu">debnick@uw.edu</a>	yes	Exomes	middle

*(If more space is required, please attach an additional page with this information, Thank you.)*

5. Names of proposed NON ESP GO Writing Team members including affiliations and E-mail addresses.  
 a. I Elisabeth Rosenthal attest that all NON ESP GO Writing Team members have reviewed and approved this manuscript proposal.

Name/Degree	Affiliation	E-Mail Address	Junior Investigator	Author/Role Contribution	Author Position
Jane Ranchalis	UW, Jarvik Lab	<a href="mailto:janer@u.washington.edu">janer@u.washington.edu</a>	no	Wet lab	middle
John D. Brunzell	UW	<a href="mailto:jbrunzell@medicine.washington.edu">jbrunzell@medicine.washington.edu</a>	no	Collected patients	middle
Arno G. Motulsky	UW	<a href="mailto:agmot@u.washington.edu">agmot@u.washington.edu</a>	no	Collected patients	middle
Ellen M. Wijsman	UW	<a href="mailto:wijzman@uw.edu">wijzman@uw.edu</a>	no	Statistical and computational support	middle
Amber Burt	UW	<a href="mailto:aaburt@uw.edu">aaburt@uw.edu</a>	no	Computational support	middle

*(If more space is required, please attach an additional page with this information)*

6. I Elisabeth Rosenthal agree to comply with the NIH Public Access Policy

## II. SCIENTIFIC INFORMATION

### 1. Scientific Rationale (please be specific and concise)

We are verifying an association between SLC25A40 variants and triglyceride level. We have found a novel variant that segregates with high triglycerides in a large family. Since our variant is novel, we would like to verify that the gene has a relationship with triglyceride levels.

### 2. Objectives and Plan (with timeline)

#### a. Main Question / Hypotheses

We hypothesize that rare ( $q < 0.001$ ) high GERP ( $> 5$ ) SNVs in SLC25A40 associate with high triglycerides.

#### b. Study Populations

We use all individuals that have measured triglycerides. This includes the following cohorts:

Broad: EOMI contains ESP cohorts PennCATH, TRIUMPH, and Cleveland Clinic

HeartGO contains ESP cohorts ARIC, CARDIA, CHS, FHS, JHS and MESA

WHISP contains ESP cohort WHI

#### c. Main Statistical analysis plans and methods

We use linear models, and adjust for age, sex, and race.

Added 7/12/13:

Methods using the NHLBI GO ESP data:

We sought confirmation of association with TG for any gene containing a novel SNV that remained associated with the trait after genotyping of the full pedigree. Using TG data from unrelated individuals in the PennCATH, TRIUMPH, Cleveland Clinic, ARIC, CARDIA, CHS, FHS, JHS, MESA and WHI cohorts in the dbGaP posted ESP data {{840 NHLBI GO Exome Sequencing Project (ESP)}} March 2013, (see supplementary material), we combined all rare ( $MAF < 0.5\%$ ) missense, nonsense and splice sites with  $GERP > 4.8$  into a single genotype factor (1=presence of a minor allele and 0=absence of all minor alleles) in individuals with measured TG. We used a GERP cutoff of 4.8 since this is the 75<sup>th</sup> percentile for GERP of all identifiable LDL-raising pathogenic SNPs in *LDLR* {{826 Kent, W.J. 2002; 827 Davydov, E.V. 2010; 828 Cooper, G.M. 2005; 829 Sherry, S.T. 2001}} (data not shown). We assumed that individuals missing genotypes at these rare SNVs were non-carriers. We performed this two-sided whole gene test using a linear model for  $\log(TG)$  on the 0, 1 genotype factor, using the package R {{786 R Core Team 2012}} with and without adjusting for race (first 3 principal components or ethnic group), age, and sex.

#### d. Location of Analysis

UW

### 3. Sources of Data to be used – Provide rationale for any data

Broad: EOMI contains ESP cohorts PennCATH, TRIUMPH, and Cleveland Clinic

HeartGO contains ESP cohorts ARIC, CARDIA, CHS, FHS, JHS and MESA

WHISP contains ESP cohort WHI

### 4. List of Sources

Subset of ESP6800 data release that have measured triglycerides

### 5. Aggregate summary data to be generated by investigator of studies selected above.

Table including age, sex and race, broken down by quantile in  $\log(\text{triglyceride})$ .

### 6. Conflict of Interest:

Do you or any member of your WG/PT or PWG intend to patent and process? Y/N: NO

7. I Elisabeth Rosenthal affirm that this proposal has been reviewed and approved by the Lipids Project team Project Team and by all listed investigators, I further affirm that the project team conveners, Leslie Lange and Russ Tracy, concur in this statement.

### 8. References (Limit 15)

1. Heath, S. C. 1997. Markov Chain Monte Carlo Segregation and Linkage Analysis for Oligogenic Models. *Am. J. Hum. Genet.* 61: 748-760.
2. Igo, J., Robert P., E. M. Wijsman. 2008. Empirical significance values for linkage analysis: Trait simulation using posterior model distributions from MCMC oligogenic segregation analysis. *Genet. Epidemiol.* 32: 119-131.
3. Rosenthal, E. A., E. M. Wijsman. 2010. Joint linkage and segregation analysis under multiallelic trait inheritance: simplifying interpretations for complex traits. *Genet. Epidemiol.* 34: 344-353.
4. Thompson, E. A. 2005. MCMC in the Analysis of Genetic Data on Pedigrees. In *Markov Chain Monte Carlo: Innovations and Applications*. F. Liang, J. Wang and W. Kendall, editors. World Scientific Co Pte Ltd, Singapore. 183-216.

5. Wijsman, E. M., J. H. Rothstein, and E. A. Thompson. 2006. Multipoint linkage analysis with many multiallelic or dense diallelic markers: Markov chain-Monte Carlo provides practical approaches for genome scans on general pedigrees. *Am. J. Hum. Genet.* 79: 846-858.
6. Tong, L., E. A. Thompson. 2008. Multilocus lod scores in large pedigrees: Combination of exact and approximate calculations. *Hum. Hered.* 65: 142-153.
7. Thompson, E. A. 2011. The structure of genetic linkage data: from LIPED to 1M SNPs. *Hum. Hered.* 71: 88-98.
8. Boerwinkle, E., R. Chakraborty, and C. F. Sing. 1986. The Use of Measured Genotype Information in the Analysis of Quantitative Phenotypes in Man .1. Models and Analytical Methods. *Ann. Hum. Genet.* 50: 181-194.
9. Almasy, L., J. Blangero. 2004. Exploring Positional candidate genes: Linkage conditional on measured genotype. *Behav. Genet.* 34: 173-177
10. Adzhubei, I. A., S. Schmidt, L. Peshkin, V. E. Ramensky, A. Gerasimova, P. Bork, A. S. Kondrashov, and S. R. 11. Sunyaev. 2010. A method and server for predicting damaging missense mutations. *Nat. Methods* 7: 248-249
12. Pontius, J. U., L. Wagner, and G. D. Schuler. 2003. UniGene: a unified view of the transcriptome. In *The NCBI Handbook*. J. McEntyre and J. Ostell, editors. National Center for Biotechnology Information, Bethesda, MD.
13. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators. 2012. Effects of dalcetrapib in patients with a recent acute coronary syndrome. *N Engl J Med.* 29;367(22):2089-99.
14. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J. 2010. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, *Lancet.* 8;375(9726):1634-9. Erratum in: *Lancet.* 2010 Jul 10;376(9735):90. Kastelein, J J
15. Rosenthal EA, Ronald J, Rothstein J, Rajagopalan R, Ranchalis J, Wolfbauer G, Albers JJ, Brunzell JD, Motulsky AG, Rieder MJ, Nickerson DA, Wijsman EM, Jarvik GP. 2011. Linkage and association of phospholipid transfer protein activity to LASS4. *J Lipid Res.* 52(10):1837-46.